Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Oramed Pharm ( (ORMP) ) has provided an announcement.
On September 30, 2025, Oramed Pharmaceuticals Inc. completed the first tranche of a warrant repurchase agreement with Scilex Holding Company, selling 3,130,000 shares of Scilex’s common stock for $13,000,000. Scilex retains the option to repurchase the remaining 3,370,000 shares for $14,000,000 by December 31, 2025, potentially impacting Oramed’s financial position and market strategy.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
Oramed Pharm’s overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on developing innovative oral drug delivery systems.
Average Trading Volume: 89,450
Technical Sentiment Signal: Hold
Current Market Cap: $100M
See more data about ORMP stock on TipRanks’ Stock Analysis page.